Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation

Histopathology

Volumn 47, Issue 6, 2005, Pages 611-616

  Bratthauer, Gary L ^a   Saenger, J S ^a,b   Strauss, B L ^a,c  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Breast; Cytoplasm; Immunohistochemistry; p63; Secretory carcinoma; Secretory change

Indexed keywords

PROTEIN ANTIBODY; PROTEIN P63;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; APOCRINE GLAND; ARTICLE; BREAST; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER INVASION; CELL DIFFERENTIATION; CELL FUNCTION; CELL SECRETION; CELL TRANSFORMATION; CELL VACUOLE; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; MYOEPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ANTIBODIES; BREAST; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CYTOPLASM; DNA-BINDING PROTEINS; EPITHELIAL CELLS; FEMALE; FIBROCYSTIC BREAST DISEASE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 28844455327     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02282.x     Document Type: Article

References (22)

1. Levrero M, De Laurenzi V, Costanzo A et al. Structure, function, and regulation of p63 and p73. Cell Death Differ. 1999; 6; 1146-1153.
2. Yang A, Kaghad M, Wang Y et al. p63, a p53 homologue at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 1998; 2; 305-316.
3. Patturajan M, Nomoto S, Sommer M et al. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1; 369-379.
4. Signoretti S, Waltregny D, Dilks J et al. p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 2000; 157; 1769-1775.
5. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod. Pathol. 2002; 15; 1302-1308.
6. Shah RB, Zhou M, LeBlanc M et al. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am. J. Surg. Pathol. 2002; 26; 1161-1168.
7. Werling RW, Hwang H, Yaziji H et al. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am. J. Surg. Pathol. 2003; 27; 82-90.
8. Babareshci M, Pecciarini L, Cangi MG et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am. J. Surg. Pathol. 2001; 23; 1054-1060.
9. Di Como CJ, Urist MJ, Babayan I et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 2002; 8; 494-501.
10. Foschini MP, Gaiba A, Cocchi R et al. Pattern of p63 expression in squamous cell carcinoma of the oral cavity. Virchows Arch. 2004; 444; 332-339.
11. Stefanou D, Batistatou A, Nonni A et al. p63 expression in benign and malignant breast lesions. Histol. Histopathol. 2004; 19; 465-471.
12. Batistatou A, Stefanou D, Arkoumani E et al. The usefulness of p63 as a marker of breast myoepithelial cells. In Vivo 2003; 17; 573-576.
13. Bratthauer GL. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods. Meth. Mol. Biol. 1999; 115; 203-214.
14. Weber A, Langhanki L, Schütz A et al. Expression profiles of p53, p63, and p73 in benign salivary gland tumors. Virchows Arch. 2002; 441; 428-436.
15. Lannon CL, Martin MJ, Tognon CE et al. A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation. J. Biol. Chem. 2004; 279; 6225-6234.
16. Tognon C, Knezevich SR, Huntsman D et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2; 367-376.
17. Gisselsson D, Palsson E, Hoglund M et al. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer 2002; 33; 133-140.
18. Kadakia M, Slader C, Berberich SJ. Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol. 2001; 20; 321-330.
19. Maitra A, Tavassoli FA, Albores-Saavedra J et al. Molecular abnormalities associated with secretory carcinomas of the breast. Hum. Pathol. 1999; 30; 1435-1440.
20. Inoue T, Stuart J, Leno R et al. Nuclear import and export signals in control of the p53-related protein p73. J. Biol. Chem. 2002; 277; 15053-15060.
21. Vincek V, Knowles J, Li J et al. Expression of p63 mRNA isoforms in normal human tissue. Anticancer Res. 2003; 23; 3945-3948.
22. Bamberger C, Schmale H. Identification and tissue distribution of novel KET/p63 splice variants. FEBS Lett. 2001; 501; 121-126.